Group 1 - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][2] - The company will present at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40pm EDT in Miami, FL [1] - aTyr's lead therapeutic candidate, efzofitimod, is an immunomodulator in clinical development for treating interstitial lung disease, which involves inflammation and progressive fibrosis of the lungs [2] Group 2 - The company leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation [2] - aTyr's discovery platform aims to uncover therapeutic intervention points by exploring signaling pathways from its proprietary library of domains derived from all 20 tRNA synthetases [2] - Management will be available for one-on-one meetings with registered investors during the conference [1]
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference